Evidence map›Paper›PMID 32970241›Full record

ArticleBreast cancer research and treatment2021

Impact of patients' refusal to undergo adjuvant treatment measures on survival.

H Männle, J W Siebers, F Momm, K Münstedt

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

H MännleGynaecology and Obstetrics, Ortenau-Klinikum Offenburg-Kehl, Ebertplatz 12, 77654, Offenburg, Germany. heidrun.maennle@ortenau-klinikum.de.ORCID http://orcid.org/0000-0002-1541-595X
J W SiebersGynaecology and Obstetrics, Ortenau-Klinikum Offenburg-Kehl, Ebertplatz 12, 77654, Offenburg, Germany.
F MommRadio-oncology, Ortenau-Klinikum Offenburg-Kehl, Weingartenstr. 70, 77654, Offenburg, Germany.
K MünstedtGynaecology and Obstetrics, Ortenau-Klinikum Offenburg-Kehl, Ebertplatz 12, 77654, Offenburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBreast cancer patients receive treatment recommendations from multidisciplinary tumour boards. To determine the consequences of patients' refusal of such recommendations, we analysed the database of the Centre for Breast Cancer at the Ortenau Clinic in Offenburg, Germany.

methodsA total of 4315 patients with non-metastatic primary breast cancer, treated between 1997 and 2019, were analysed with descriptive analyses, Kaplan-Meier survival analyses, and Cox regression analyses regarding the effects of their refusal.

resultsAbout 10.7% of the patients rejected the treatment advice. These were significantly elderly (F = 74.4; p < 0.001; one-way ANOVA), with greater tumour size (F = 36.7; p < 0.001; one-way ANOVA), a higher number of affected lymph nodes (F = 4.2; p = .039; one-way ANOVA), and more poorly differentiated tumours (χ

conclusionsAll parts of the adjuvant treatment of breast cancer are clearly associated with improvements regarding disease-free and overall survival. To answer open questions about the background of patients' refusal, an analysis of prospective data collections seems necessary. In addition, patient communication should be improved so that patients understand the background of the multidisciplinary tumour board and the potential consequences of their refusal.

Indexed as

Breast NeoplasmsAgedChemotherapy, AdjuvantFemaleGermanyHumansKaplan-Meier EstimateNeoplasm Recurrence, LocalProspective StudiesRadiotherapy, AdjuvantBreats cancerRefusal of adjuvant treatmentTumour board recommendation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.